Neurological diseases encompass over 400 conditions that affect the brain, spinal cord, or peripheral nervous system. These disorders are classified based on symptom onset and progression rather than the specific organs affected.
Types of Neurological Diseases
- Sudden Onset Disorders: Resulting from acute events like strokes, cerebral bleeding, or traumatic injuries to the brain or spinal cord.
- Intermittent Disorders: Characterized by unpredictable attacks or flare-ups, such as multiple sclerosis (MS) and seizure disorders.
- Progressive Conditions: Gradually worsening diseases like Alzheimer’s or amyotrophic lateral sclerosis (ALS).
- Stable Conditions: Non-progressive conditions that often result from birth or trauma, such as cerebral palsy.
Management of Neurological Diseases
Traditional management focuses on slowing disease progression, reducing flare-ups, and improving quality of life. For degenerative conditions, treatment often addresses chronic pain and mobility limitations. In stable or sudden-onset conditions, rehabilitation and physical therapy aim to restore or maintain function.
MSC Therapy for Neurological Diseases
Mesenchymal stromal cells (MSCs) are emerging as a groundbreaking treatment option for neuroinflammatory and degenerative diseases, particularly those involving demyelination. These cells offer multiple therapeutic benefits:
- Anti-Inflammatory and Immune Regulation: MSCs can reduce chronic inflammation, halting the progressive loss of myelin observed in conditions like MS and ALS.
- Neural Regeneration: MSCs can be differentiated into specific neural cells, targeting the needs of different conditions:
- Oligodendrocytes for myelin production in MS or ALS.
- Astrocytes for dopamine production in Parkinson’s disease.
- Other motor neurons, potentially benefiting autism spectrum disorder or related conditions.
By addressing the underlying mechanisms of demyelination and nerve damage, MSC therapy provides a scientifically and clinically supported approach to neurological disease treatment.
Deep Transmagnetic Stimulation (DTS)
DTS uses low-energy acoustic shockwaves to stimulate deep tissues, traditionally focusing on reversing demyelination by promoting myelin production. At Biotherapy International, DTS is now being explored as a complement to MSC therapy:
- DTS enhances the targeting and mobilization of MSCs.
- It activates growth factors without requiring additional bone marrow extractions.
This has already been approved in Israel, Europe, and the United States to treat:
- Alzheimer’s Disease
- Autism and Asperger’s Disorder
- Bipolar Depression, Schizophrenia – Negative Symptoms
- Chronic diabetic pain
- Major Depression (with Antidepressants and as mono-therapy)
- Multiple Sclerosis (MSC)
- Obsessive-Compulsive Disorder (OCD)
- Parkinson Disease (with anti-parkinsonian medications)
- Post-Traumatic Stress Disorder (PTSD)
- Stroke
A New Frontier in Neurological Treatment
The combination of MSC therapy and DTS represents a revolutionary step in regenerative medicine. These approaches offer new hope for patients with neurological diseases once considered irreversible, enabling targeted and effective treatment for conditions like MS, ALS, Parkinson’s disease, and more. Biotherapy International continues to lead the way in developing innovative therapies to restore function and improve patients’ quality of life.
